Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
207 CHF | +0.24% | -1.66% | +13.86% |
05-28 | HBM Healthcare Flags NAV Boost from Yellow Jersey-Johnson & Johnson Deal | MT |
05-23 | HBM Healthcare Investments' Portfolio Company to Buy Laboratorios Biopas Group | MT |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Weaknesses
- Based on current prices, the company has particularly high valuation levels.
Ratings chart - Surperformance
Sector: Investment Management & Fund Operators
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+13.86% | 1.56B | - | ||
+21.66% | 3.24B | B- | ||
+12.50% | 1.76B | - | - | |
-11.54% | 1.22B | - | - | |
+33.29% | 902M | B+ | ||
+7.52% | 651M | - | ||
+56.73% | 651M | - | D+ | |
-4.17% | 503M | - | - | |
+19.88% | 434M | - | - | |
+34.39% | 320M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- HBMN Stock
- HBMNE Stock
- Ratings HBM Healthcare Investments AG